[1] |
Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer, 2020, 126(11): 2666-2678.
|
[2] |
陈圣, 陈国想, 何中明, 等. 微小RNA在胆管癌发生发展中的作用[J]. 临床肝胆病杂志, 2021, 37(9): 2241-2245.
|
[3] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[4] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
|
[5] |
Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444.
|
[6] |
Dinges SS, Hohm A, Vandergrift LA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations[J]. Nat Rev Urol, 2019, 16(6): 339-362.
|
[7] |
Hirotsu T, Sonoda H, Uozumi T, et al. A highly accurate inclusive cancer screening test using caenorhabditis elegans scent detection[J]. PLoS One, 2015, 10(3): e0118699.
|
[8] |
Guan MC, Ouyang W, Wang MD, et al. Biomarkers for hepatocellular carcinoma based on body fluids and feces[J]. World J Gastrointest Oncol, 2021, 13(5): 351-365.
|
[9] |
Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma[J]. Br J Cancer, 1997, 75(10): 1460-1466.
|
[10] |
Abdalla MA, Haj-Ahmad Y. Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients[J]. J Cancer, 2012, 3: 390-403.
|
[11] |
Chiou SH, Lee KT. Proteomic analysis and translational perspective of hepatocellular carcinoma: identification of diagnostic protein biomarkers by an onco-proteogenomics approach[J]. Kaohsiung J Med Sci, 2016, 32(11): 535-544.
|
[12] |
Zhan Z, Guan Y, Mew K, et al. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(2): G305-G312.
|
[13] |
Zhao Y, Li Y, Liu W, et al. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics[J]. J Proteomics, 2020, 225: 103780.
|
[14] |
Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders[J]. Gut, 2013, 62(1): 122-130.
|
[15] |
Duangkumpha K, Stoll T, Phetcharaburanin J, et al. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis[J]. PLoS One, 2019, 14(8): e0221024.
|
[16] |
Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics[J]. Mol Cell Proteomics, 2008, 7(10): 1850-1862.
|
[17] |
Aitekenov S, Gaipov A, Bukasov R. Review: detection and quantification of proteins in human urine[J]. Talanta, 2021, 223(Pt 1): 121718.
|
[18] |
Jain S, Lin SY, Song W, et al. Urine-based liquid biopsy for nonurological cancers[J]. Genet Test Mol Biomarkers, 2019, 23(4): 277-283.
|
[19] |
Kim AK, Hamilton JP, Lin SY, et al. Urine DNA biomarkers for hepatocellular carcinoma screening[J]. Br J Cancer, 2022, 126(10): 1432-1438.
|
[20] |
Liu Z, Wang Y, Dou C, et al. MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 49.
|
[21] |
Zhang Z, Zhang Y, Sun XX, et al. MicroRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma[J]. Mol Cancer, 2015, 14: 5.
|
[22] |
Ye Y, Zhuang J, Wang G, et al. MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1[J]. Exp Ther Med, 2018, 15(1): 1150-1158.
|
[23] |
Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients[J]. J Cancer, 2012, 3: 19-31.
|
[24] |
Świtlik WZ, Bielecka-Kowalska A, Karbownik MS, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: A preliminary study[J]. Biomark Med, 2019, 13(7): 523-534.
|
[25] |
Zhou G, Zeng Y, Luo Y, et al. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma[J]. Eur J Surg Oncol, 2022, 48(1): 95-102.
|
[26] |
Silakit R, Loilome W, Yongvanit P, et al. Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group[J]. Parasitol Int, 2017, 66(4): 479-485.
|
[27] |
Kobori K, Sakakibara H, Maruyama K, et al. A rapid method for determining urinary indoleacetic acid concentration and its clinical significance as the tumor-marker in the diagnosis of malignant diseases[J]. J UOEH, 1983, 5(2): 213-220.
|
[28] |
Saichua P, Yakovleva A, Kamamia C, et al. Levels of 8-OxodG predict hepatobiliary pathology in opisthorchis viverrini endemic settings in Thailand[J]. PLoS Negl Trop Dis, 2015, 9(7): e0003949.
|
[29] |
Nanashima A, Izumino H, Sumida Y, et al. Relationship between urinary 8-hydroxydeoxyguanine (8-OhdG) levels and clinicopathological findings in hepatobiliary malignancies[J]. Anticancer Res, 2016, 36(8): 3899-3903.
|
[30] |
Yuan JM, Grouls M, Carmella SG, et al. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma[J]. Carcinogenesis, 2019, 40(8): 989-997.
|
[31] |
Ladep NG, Dona AC, Lewis MR, et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans[J]. Hepatology, 2014, 60(4): 1291-1301.
|
[32] |
Haznadar M, Diehl CM, Parker AL, et al. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10): 1704-1711.
|
[33] |
Sun L, Su Y, Liu X, et al. Serum and exosome long non-coding RNAs as potential biomarkers for hepatocellular carcinoma[J]. J Cancer, 2018, 9(15): 2631-2639.
|
[34] |
Lapitz A, Arbelaiz A, O’Rourke CJ, et al. Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis[J]. Cells, 2020, 9(3): 721.
|
[35] |
Kim J, Kang W, Sinn DH, et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients[J]. Clin Mol Hepatol, 2020, 26(4): 516-528.
|
[36] |
Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangio-carcinoma[J]. Oncol Rep, 2013, 29(4): 1259-1267.
|
[37] |
Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5): 52.
|